抑制IL-1β与减少动脉粥样硬化血栓性心血管事件:CANTOS试验
CANTOS试验将10,061例既往心肌梗死且高敏C反应蛋白≥2 mg/l的患者随机分配至安慰剂或卡那奴单抗50/150/300 mg每3个月一次,中位随访3.7年。卡那奴单抗显著降低总严重心血管事件发生率,各剂量组率比(95%CI)分别为0.80(0.69-0.93)、0.79(0.68-0.92)和0.78(0.67-0.91)。
要点
- 卡那奴单抗可减少既往心梗且残余炎症风险患者的总心血管事件负担。
- 50、150、300 mg每3个月一次均显著降低总严重心血管事件发生率。
- 总严重心血管事件包括心梗、卒中、冠脉血运重建和心血管死亡。
核心结论
- 卡那奴单抗抗炎治疗显著减少既往心梗且存在残余炎症风险患者的总心血管事件数。
研究设计与样本
- 随机对照试验,10,061例患者随机分配至安慰剂或卡那奴单抗50 mg、150 mg、300 mg每3个月一次。
- 采用负二项回归估计率比及95%CI,并校正同一个体重复事件的关联。
主要发现
- 中位随访3.7年,10,061例随机患者中2,003例发生3,417次总严重心血管事件。
- 安慰剂、50 mg、150 mg、300 mg组总严重心血管事件每100人年发生率分别为10.4、8.4、8.3、8.2。
- 与安慰剂相比,率比(95%CI)分别为50 mg 0.80(0.69-0.93)、150 mg 0.79(0.68-0.92)、300 mg 0.78(0.67-0.91)。
关键数值与推荐
- 入选患者为既往心肌梗死且高敏C反应蛋白≥2 mg/l。
- 总严重心血管事件复合终点包括心梗、卒中、冠脉血运重建和心血管死亡。
临床怎么用
- 对于既往心梗且残余炎症风险(hsCRP≥2 mg/l)患者,卡那奴单抗每3个月一次可降低总严重心血管事件负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab significantly reduces the first major adverse cardiovascular event in patients with prior myocardial infarction (MI) and residual inflammatory risk (high-sensitivity C-reactive protein ≥ 2 mg/l). However, the effect of canakinumab on the total number of cardiovascular events, including recurrent events collected after a first event, is unknown. OBJECTIVES: This study sought to determine whether randomly allocated canakinumab would reduce the total burden of serious cardiovascular events. METHODS: We randomized 10,061 patients to placebo or canakinumab 50 mg, 150 mg, or 300 mg once every 3 months and compared the rates of the composite of all serious cardiovascular events (MI, stroke, coronary revascularization, and cardiovascular death) in active versus placebo groups. We used negative binomial regression to account for correlations among repeated events in the same person and to estimate rate ratios and 95% confidence intervals. RESULTS: During a median of 3.7 years of follow-up, 3,417 total serious cardiovascular events occurred in 2,003 individuals among the 10,061 unique patients randomized. Canakinumab reduced the rates of total serious cardiovascular events, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg canakinumab groups of 10.4, 8.4, 8.3, and 8.2, respectively. The corresponding rate ratios (95% confidence intervals) compared with placebo were 0.80 (0.69 to 0.93) for 50 mg, 0.79 (0.68 to 0.92) for 150 mg, and 0.78 (0.67 to 0.91) for 300 mg. CONCLUSIONS: Anti-inflammatory therapy with canakinumab significantly reduced the total number of cardiovascular events in patients with prior MI and evidence of residual inflammatory risk. (Cardiovascular Risk Reduction Study [Reduction in Recurrent Major CV Disease Events] (CANTOS); NCT01327846.
引用
- Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020. PMID: 33004131. doi:10.1016/j.jacc.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。